Loading
Life sciences · Journal article
European Heart Journal - Case Reports · September 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Structured abstract Background Obesity is a major modifiable risk factor for atrial fibrillation (AF) and has been linked to processes involved in atrial structural and electrical remodelling. Glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular events in patients with type 2 diabetes at high cardiovascular risk and are increasingly regarded as cardiometabolic therapies. Whether these agents modify the trajectory of atrial cardiomyopathy or exert direct antiarrhythmic effects beyond their metabolic actions remains an area of active investigation. Case summary A 50-year-old man with obesity (body mass index 34.9 kg/m2) and persistent AF presented with persistent symptomatic episodes despite four prior pulmonary vein isolation procedures and repeated electrical cardioversions. Rhythm monitoring was performed continuously using a wearable device since 2023, documenting recurrent episodes lasting 8–30 hours with an mEHRA class IIb–III symptom burden. Echocardiography demonstrated preserved left ventricular systolic function and left atrial enlargement. In January 2026, once-weekly subcutaneous semaglutide was initiated for weight management (0.25 mg/week with subsequent dose escalation). While a weight reduction of 14 kg was observed within six months, AF episodes and symptoms ceased immediately after treatment initiation and have not recurred during follow-up. Conclusion This case describes cessation of recurrent AF episodes following initiation of semaglutide in a patient with obesity and prior ablation failure. Potential mechanisms may include cardiometabolic effects as well as direct myocardial effects on sodium and calcium handling that have been described experimentally. Although a causal relationship cannot be established from a single observation, this finding may serve as a hypothesis-generating signal and provide a rationale for prospective studies evaluating cardiometabolic therapies as potential adjuncts in rhythm control strategies.